CHICAGO -- A mutation-agnostic gene therapy for retinitis pigmentosa (RP) showed promise for improving vision in severely vision-impaired and blind patients, a randomized clinical trial showed. After ...
In advanced dry disease, a key problem is failure of retinal pigment epithelium, often shortened to RPE. These cells help ...
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies ...
Scientists at USC are launching a new trial to test a tiny stem cell implant that could restore vision in people with advanced dry macular degeneration. The hair-thin patch replaces damaged retinal ...
Please provide your email address to receive an email when new articles are posted on . MCO-010, a mutation-agnostic gene therapy, demonstrated vision improvement in retinitis pigmentosa. Nanoscope ...
SEATTLE--(BUSINESS WIRE)--LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the 24-month data from its LIGHTSITE III, ...
Want to improve your eyesight? Discover 5 simple tips, from eating eye-healthy foods to taking screen breaks, to protect your ...
Age-related macular degeneration (AMD) is a leading cause of vision loss among people aged 50 and older. While treatments for the wet form of AMD have shown promise, the dry form, which accounts for ...
Patients with presbyopia had consistent and durable vision improvement across multiple doses of a combination eye drop solution, a large retrospective review showed. From 69% to 99% of patients had ...
Nanoscope Therapeutics has agreed with the US Food and Drug Administration (FDA) on the design of its Phase III trial following a successful Phase II study of its gene therapy in Stargardt disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback